An antibody–drug conjugate targeting N-glycosylated CEACAM5/6; the tumor-targeting monoclonal antibody is internalized and releases the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor that induces mitotic arrest and cell death.
Antibody binds N-glycosylated CEACAM5/6 on tumor cells, is internalized, and releases the MMAE payload, which binds tubulin and inhibits microtubule polymerization, leading to G2/M arrest and apoptotic cell death in CEACAM5/6-expressing cells.
ADC antibody binds CEACAM5 on tumor cells, is internalized, and releases MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptotic cell death.
An antibody–drug conjugate targeting N-glycosylated CEACAM5/6; the tumor-targeting monoclonal antibody is internalized and releases the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor that induces mitotic arrest and cell death.
Antibody binds N-glycosylated CEACAM5/6 on tumor cells, is internalized, and releases the MMAE payload, which binds tubulin and inhibits microtubule polymerization, leading to G2/M arrest and apoptotic cell death in CEACAM5/6-expressing cells.
ADC antibody binds N-glycosylated CEACAM6 on tumor cells, is internalized, and releases MMAE, which inhibits microtubule polymerization causing G2/M arrest and apoptosis.
Intravenous anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis; used when co-occurring B-cell lymphoproliferation is present.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC (e.g., NK cells/macrophages) and complement-dependent cytotoxicity (CDC), and can also induce apoptosis upon CD20 crosslinking.
Chimeric anti-CD20 IgG1 monoclonal antibody that depletes B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and eliminates them via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity, and induction of apoptosis upon CD20 crosslinking.
Humanized monoclonal antibody that binds HER2 domain IV to inhibit HER2 signaling and mediate antibody-dependent cellular cytotoxicity (ADCC) via Fcγ receptors. Administered as part of PHESGO in this study.
Humanized IgG1 monoclonal antibody that binds HER2 (domain IV), inhibits HER2 signaling and receptor activation/heterodimerization, promotes receptor downregulation, and mediates Fcγ receptor–dependent ADCC against HER2-overexpressing tumor cells.
Trastuzumab binds HER2 on tumor cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC, leading to perforin/granzyme-dependent killing; may also contribute some CDC and growth inhibition via HER2 blockade.